Illumina (NASDAQ:ILMN) Stock Price Expected to Rise, Royal Bank Of Canada Analyst Says

Illumina (NASDAQ:ILMN) had its price target raised by stock analysts at Royal Bank Of Canada from $230.00 to $310.00 in a report released on Monday, Benzinga reports. The firm presently has an “outperform” rating on the life sciences company’s stock. Royal Bank Of Canada’s target price indicates a potential upside of 13.33% from the stock’s previous close.

Several other research firms have also weighed in on ILMN. Guggenheim lifted their price objective on shares of Illumina from $226.00 to $305.00 and gave the stock a “buy” rating in a research note on Thursday, October 1st. UBS Group raised shares of Illumina from a “neutral” rating to a “buy” rating and upped their target price for the company from $135.00 to $260.00 in a research note on Wednesday, September 9th. Deutsche Bank Aktiengesellschaft lowered shares of Illumina to a “hold” rating in a report on Wednesday, August 5th. Piper Sandler lifted their price target on shares of Illumina from $225.00 to $305.00 and gave the stock an “overweight” rating in a research report on Monday, September 28th. Finally, Leerink Partners boosted their price target on shares of Illumina from $220.00 to $300.00 and gave the company an “outperform” rating in a report on Tuesday, September 29th. Ten equities research analysts have rated the stock with a Buy rating, six have given a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat.com, Illumina presently has an average rating of “Hold” and a consensus price target of $219.69.

Illumina Trading Down 6.9%

NASDAQ ILMN opened at $273.54 on Monday. Illumina has a 12 month low of $88.00 and a 12 month high of $309.35. The stock has a 50-day simple moving average of $223.07 and a 200 day simple moving average of $178.23. The company has a current ratio of 1.80, a quick ratio of 1.40 and a debt-to-equity ratio of 0.53. The company has a market capitalization of $41.30 billion, a PE ratio of 51.03, a P/E/G ratio of 4.16 and a beta of 1.41.

Illumina (NASDAQ:ILMN) last issued its earnings results on Thursday, July 30th. The life sciences company reported $1.31 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.23 by $0.08. The firm had revenue of $1.16 billion for the quarter, compared to analysts’ expectations of $1.13 billion. Illumina had a return on equity of 29.84% and a net margin of 18.36%.The company’s revenue was up 9.4% compared to the same quarter last year. During the same quarter last year, the business earned $1.19 earnings per share. Illumina has set its FY 2026 guidance at 5.300-5.400 EPS. Research analysts forecast that Illumina will post 5.36 EPS for the current year.

Insider Activity

In related news, Director Keith Meister sold 457,858 shares of the business’s stock in a transaction that occurred on Tuesday, August 4th. The stock was sold at an average price of $200.10, for a total value of $91,617,385.80. Following the completion of the transaction, the director directly owned 2,372,694 shares in the company, valued at approximately $474,776,069.40. The trade was a 16.18% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. In the last three months, insiders sold 2,061,850 shares of company stock valued at $436,479,102. 2.90% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the stock. BlackRock Inc. acquired a new stake in shares of Illumina in the 2nd quarter valued at about $3,374,423,000. Plato Investment Management Ltd acquired a new position in shares of Illumina during the second quarter worth about $948,000. Mitsubishi UFJ Asset Management Co. Ltd. bought a new position in shares of Illumina during the second quarter worth about $30,501,000. Edmond DE Rothschild Holding S.A. acquired a new stake in Illumina in the 2nd quarter valued at approximately $129,792,000. Finally, Impact Partnership Wealth LLC raised its position in Illumina by 235.8% in the 1st quarter. Impact Partnership Wealth LLC now owns 11,080 shares of the life sciences company’s stock valued at $1,366,000 after buying an additional 7,780 shares during the last quarter. Institutional investors own 89.42% of the company’s stock.

Trending Headlines about Illumina

Here are the key news stories impacting Illumina this week:

• Positive Sentiment: Analyst optimism remains a key support. RBC Capital Markets raised its price target to $310 from $230 and maintained an “outperform” rating, citing improving clinical sequencing demand. RBC also characterized clinical sequencing revenue as a durable mid-teens growth opportunity. Illumina clinical sequencing revenue article
• Positive Sentiment: The recent rally was fueled by expectations for stronger clinical sales, additional business catalysts, and a potential role for genomic sequencing data as artificial-intelligence infrastructure. Illumina’s September addition to the S&P 500 may also support demand from index-tracking funds. Illumina shares rally article
• Neutral Sentiment: Illumina’s latest reported quarter exceeded consensus expectations for both earnings and revenue, while management raised full-year 2026 adjusted EPS guidance to $5.30–$5.40. These fundamentals provide longer-term support, although investors are now weighing them against the stock’s elevated valuation.
• Negative Sentiment: Barclays raised its price target to $200 from $160 but retained an underweight rating. The target remains well below recent trading levels, signaling that the bank believes expectations and valuation have outpaced near-term fundamentals. Barclays Illumina price target article
• Negative Sentiment: Reported insider activity has been heavily weighted toward selling, including substantial sales attributed to Keith Meister. While insider transactions do not necessarily reflect operating performance, the selling may add to investor caution after the recent surge. Illumina momentum and insider activity article

Illumina Company Profile

Illumina, Inc develops and manufactures technologies used to analyze genetic variation and biological function. Its products are primarily based on next-generation sequencing, a method that enables researchers and clinicians to read DNA and RNA for applications including genomic research, disease studies, drug development and clinical testing.

The company offers sequencing instruments, consumables such as reagent kits and flow cells, and related software and informatics solutions. Illumina also provides services and support designed to help customers prepare samples, run sequencing workflows, interpret genomic data and integrate results into research or clinical operations.

Founded in 1998 and headquartered in San Diego, California, Illumina serves customers worldwide, including academic and government research institutions, pharmaceutical and biotechnology companies, hospitals, clinical laboratories and other healthcare organizations.